Maria Alma Rodriguez

Peer-Reviewed Articles

1. Skardal A, Sivakumar H, Rodriguez MA, Popova LV, Dedhia PH. Bioengineered in vitro three-dimensional tumor models in endocrine cancers. Endocr Relat Cancer 31(4), 2024. e-Pub 2024. PMID: 38289290.
2. Escalona Hernández V, Padilla-Martínez II, García RAV, Rodríguez MAV, Hernández-Ortiz OJ. Synthesis, and evaluation of photophysical properties of a potential DPP-derived photosensitizer for photodynamic therapy with D-A-D architecture. J Mater Sci Mater Med 35(1):11, 2024. e-Pub 2024. PMID: 38300359.
3. Cuellar P, Castañeda-Ortiz EJ, Rosales-Zarza C, Martínez-Rodríguez CE, Canela-Pérez I, Rodríguez MA, Valdés J, Azuara-Liceaga E. Genome-Wide Classification of Myb Domain-Containing Protein Families in Entamoeba invadens. Genes (Basel) 15(2), 2024. e-Pub 2024. PMID: 38397191.
4. Olguín JE, Corano-Arredondo E, Hernández-Gómez V, Rivera-Montoya I, Rodríguez MA, Medina-Andrade I, Arendse B, Brombacher F, Terrazas LI. A Myeloid-Specific Lack of IL-4Rα Prevents the Development of Alternatively Activated Macrophages and Enhances Immunity to Experimental Cysticercosis. Pathogens 13(2), 2024. e-Pub 2024. PMID: 38392907.
5. Leiva K, Trinidad A, Gonzalez I, Espinosa A, Zwick T, Levine JE, Rodriguez MA, Lev-Tov H, Wu W, Kirsner RS, Godavarty A. Development of a Tissue Oxygenation Flow-Based Index Toward Discerning the Healing Status in Diabetic Foot Ulcers. Adv Wound Care (New Rochelle) 13(1):22-33, 2024. e-Pub 2023. PMID: 37060195.
6. Mamlouk O, Strati P, Feng L, Sun R, Ayers A, Steiner RE, Nair R, Flowers C, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed S. Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. Br J Haematol 204(1):e11-e16, 2024. e-Pub 2023. PMID: 37822075.
7. Rodríguez MA, Echevarría M, Perdomo L, Gómez-Chiari M, García S, Prats P, Serra B, Albaiges G. Prevalence of corpus callosum pathology in an unselected population. Should assessment of the corpus callosum be included in the routine 20 weeks scan?. Prenat Diagn. e-Pub 2024. PMID: 38161311.
8. Rodríguez MÁ, Crespo I, Guerra B, Del Valle M, Olmedillas H. Tailored Exercise Prescription According to Pharmacokinetic Compatibility: A New Horizon in Precision Medicine?. Curr Sports Med Rep 23(1):4-6, 2024. e-Pub 2024. PMID: 38180069.
9. Rodriguez MA, Hooker RS, Puckett KK, Kozikowski A. Demographics of Physician Associates (PAs) in Obstetrics and Gynecology: Where They Work and How They Compare to Other PAs. Obstet Gynecol Int 2024:3057597, 2024. e-Pub 2024. PMID: 38419828.
10. Rodríguez MA, Fernández LA, Díaz ML, Gallo CA, Corona M, Evans JD, Reynaldi FJ. Bacterial diversity using metagenomics of 16s rDNA in water kefir, an innovative source of probiotics for bee nutrition. Rev Argent Microbiol. e-Pub 2024. PMID: 38272730.
11. Rstakyan V, Mkhitaryan L, Baghdasaryan L, Ghaltaghchyan T, Karabekian Z, Sevoyan G, Aghayan M, Rodríguez MA. Stereolithography of ceramic scaffolds for bone tissue regeneration: Influence of hydroxyapatite/silica ratio on mechanical properties. J Mech Behav Biomed Mater 152:106421. e-Pub 2024. PMID: 38280269.
12. González JE, Rodríguez MA, Caballero E, Pardo A, Marco S, Farré R. Open-source, low-cost App-driven Internet of Things approach to facilitate respiratory oscillometry at home and in developing countries. Pulmonology. e-Pub 2023. PMID: 37968180.
13. Strati P, Jallouk A, Deng Q, Li X, Feng L, Sun R, Adkins S, Johncy S, Cain T, Steiner RE, Ahmed S, Chihara D, Fayad LE, Iyer SP, Horowitz S, Nastoupil LJ, Nair R, Hassan A, Daoud TE, Hawkins M, Rodriguez MA, Shpall EJ, Ramdial JL, Kebriaei P, Hong DS, Westin JR, Neelapu SS, Green MR. A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma. Blood Adv 7(21):6785-6789, 2023. PMID: 37389847.
14. Chen L, Young MT, Rodriguez MA, Kietzman K. Immigrants' Enforcement Experiences and Concern about Accessing Public Benefits or Services. J Immigr Minor Health 25(5):1077-1084, 2023. e-Pub 2023. PMID: 36859637.
15. Cuevas E, Rodríguez A, Perez M, Murillo-Olmos J, Morales-Castañeda B, Alejo-Reyes A, Sarkar R. Optimal evaluation of re-opening policies for COVID-19 through the use of metaheuristic schemes. Appl Math Model 121:506-523, 2023. e-Pub 2023. PMID: 37234701.
16. Rodriguez MÁ, Garcia-Segura LM, Cabezas R, Torrente D, Capani F, Gonzalez J, Barreto G. Corrigendum to "Tibolone protects T98G cells from glucose deprivation" [J. Steroid Biochem. Mol. Biol. 144 (2014) 294-303]. J Steroid Biochem Mol Biol 232:106292, 2023. e-Pub 2023. PMID: 36966021.
17. Avila Leon JL, Rivero CR, Guerrero L, Alviar JD, Rodríguez MA, Arocha AM, Pineda GG. Immediate results of the use of split-thickness skin autografts with and without acellular dermal matrix in patients with burns, a comparative study in a Colombian population. J Burn Care Res. e-Pub 2023. PMID: 37668065.
18. Dedhia PH, Sivakumar H, Rodriguez MA, Nairon KG, Zent JM, Zheng X, Jones K, Popova LV, Leight JL, Skardal A. A 3D adrenocortical carcinoma tumor platform for preclinical modeling of drug response and matrix metalloproteinase activity. Sci Rep 13(1):15508, 2023. e-Pub 2023. PMID: 37726363.
19. Sanft T, Day A, Ansbaugh S, Armenian S, Baker KS, Ballinger T, Demark-Wahnefried W, Dickinson K, Fairman NP, Felciano J, Flores TF, Friedman DL, Gabel NM, Goldman M, Henry NL, Hill-Kayser C, Hudson M, Koura D, Lee K, McDonough AL, Melisko M, Mooney K, Moore HCF, Moryl N, Neuman H, O'Connor T, Overholser L, Paskett ED, Patel C, Peterson L, Pirl W, Porpiglia A, Rodriguez MA, Schapira L, Schwartz AL, Smith S, Tevaarwerk A, Yang E, Zee P, McMillian NR, Freedman-Cass DA. NCCN Guidelines® Insights: Survivorship, Version 1.2023. J Natl Compr Canc Netw 21(8):792-803, 2023. PMID: 37549906.
20. Dosta P, Cryer AM, Dion MZ, Shiraishi T, Langston SP, Lok D, Wang J, Harrison S, Hatten T, Ganno ML, Appleman VA, Taboada GM, Puigmal N, Ferber S, Kalash S, Prado M, Rodríguez AL, Kamoun WS, Abu-Yousif AO, Artzi N. Investigation of the enhanced antitumour potency of STING agonist after conjugation to polymer nanoparticles. Nat Nanotechnol. e-Pub 2023. PMID: 37443252.
21. Zhukovsky DS, Soliman P, Liu D, Meyer M, Haider A, Heung Y, Gaeta S, Lu K, Stepan K, Stanton P, Rodriguez A, Bruera E. Patient Engagement With Early Stage Advance Care Planning at a Comprehensive Cancer Center. Oncologist 28(6):542-550, 2023. PMID: 36848260.
22. Lopez-Olivo MA, James J, James J, Krause KJ, Roth M, Palos GR, Ma H, Rodriguez A, Gilmore K, Cinciripini P, Suarez-Almazor ME. A systematic review and meta-analysis of e-cigarette use among cancer survivors. J Cancer Surviv. e-Pub 2023. PMID: 36952212.
23. Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol 41(4):JCO2200597, 2023. e-Pub 2022. PMID: 35952327.
24. Bravo-Vázquez LA, Mora-Hernández EO, Rodríguez AL, Sahare P, Bandyopadhyay A, Duttaroy AK, Paul S. Current Advances of Plant-Based Vaccines for Neurodegenerative Diseases. Pharmaceutics 15(2), 2023. e-Pub 2023. PMID: 36840033.
25. Dosta P, Puigmal N, Cryer AM, Rodríguez AL, Scott E, Weissleder R, Miller MA, Artzi N. Polymeric microneedles enable simultaneous delivery of cancer immunomodulatory drugs and detection of skin biomarkers. Theranostics 13(1):1-15, 2023. e-Pub 2023. PMID: 36593949.
26. Bravo-Vázquez LA, Méndez-García A, Rodríguez AL, Sahare P, Pathak S, Banerjee A, Duttaroy AK, Paul S. Applications of nanotechnologies for miRNA-based cancer therapeutics: current advances and future perspectives. Front Bioeng Biotechnol 11:1208547, 2023. e-Pub 2023. PMID: 37576994.
27. Rodriguez MA, Hooker RS. Procedures by Physician Associates in Obstetrics and Gynecology. Womens Health Rep (New Rochelle) 4(1):536-543, 2023. e-Pub 2023. PMID: 38023373.
28. Tu H, McQuade JL, Davies MA, Huang M, Xie K, Ye Y, Chow WH, Rodriguez A, Wu X. Body mass index and survival after cancer diagnosis: A pan-cancer cohort study of 114 430 patients with cancer. Innovation (Camb) 3(6):100344, 2022. e-Pub 2022. PMID: 36353671.
29. Sanft T, Day A, Peterson L, Rodriguez MA, Ansbaugh S, Armenian S, Baker KS, Ballinger T, Broderick G, Demark-Wahnefried W, Dickinson K, Fairman NP, Friedman DL, Goldman M, Henry NL, Hill-Kayser C, Hudson M, Khakpour N, Koura D, McDonough AL, Melisko M, Mooney K, Moore HCF, Moryl N, Neuman H, O'Connor T, Overholser L, Paskett ED, Patel C, Pirl W, Porpiglia A, Ruddy KJ, Schapira L, Shockney L, Smith S, Syrjala KL, Tevaarwerk A, Yang EH, Zee P, McMillian NR, Freedman-Cass DA. NCCN Guidelines® Insights: Survivorship, Version 1.2022. J Natl Compr Canc Netw 20(10):1080-1090, 2022. PMID: 36240847.
30. Rodríguez A, Cuevas E, Zaldivar D, Morales-Castañeda B, Sarkar R, Houssein EH. An agent-based transmission model of COVID-19 for re-opening policy design. Comput Biol Med 148:105847, 2022. e-Pub 2022. PMID: 35932728.
31. Cherng H.-J.J,Chuang H.H., Steiner R, Fayad L, Strati P., Nair R., Hagemeister F., Nastoupil L.J, Lee H.J, Neelapu S.S., Flowers C.R., Samaniego F., Rodriguez M., Macapinlac H.A., Feng L., Westin J.. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma 63(1):74-83, 2022.
32. Palos, Guadalupe R ; Gilmore, Katherine Ramsey ; Chapman, Patricia Hansberry ; Rodriguez, Maria Alma. Implementation of ePROs in the care of long-term cancer survivors. Journal of Clinical Oncology 39:334-334, 2021.
33. Rodriguez MA, Suarez-Almazor M, R Palos G. Guest Editors' Introduction. J Natl Cancer Inst Monogr 2021(57):1-2, 2021. PMID: 34478506.
34. Gilmore KR, Rodriguez MA. Identifying Optimal Program Models and Clinical Tools for Follow-Up Care. J Natl Cancer Inst Monogr 2021(57):18-22, 2021. PMID: 34478511.
35. Alfano CM, Suarez-Almazor M, Rodriguez MA, Palos GR, Gilmore KR. Innovating the Personalization of Stratified Survivorship Care Pathways: Using a Cancer Data Ecosystem to Improve Care Access, Outcomes, Efficiency, and Costs. J Natl Cancer Inst Monogr 2021(57):3-9, 2021. PMID: 34478510.
36. Greenbaum, U; Strati, P; Saliba, RM; Torres, J; Rondon, G; Nieto, Y; Hosing, C; Srour, SA; Westin, J; Fayad, LE; Lee, HJ; Iyer, SP; Nair, R; Nastoupil, LJ; Parmar, S; Rodriguez, MA; Samaniego, F; Steiner, RE; Wang, M; Pinnix, CC; Flowers, CR; Tummala, S; Ramdial, JL; Yalniz, FF; Hawkins, M; Rezvani, K; Champlin, RE; Shpall, EJ; Neelapu, SS; Kebriaei, P; Ahmed, S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Advances 5(14):2799-2806, 2021.
37. Augustyn A, Medeiros LJ, Ludmir EB, Gunther J, Fang P, Li S, Ok CY, Bankston ME, Verma V, Pasalic D, Ahmed S, Nastoupil LJ, Westin JR, Strati P, Neelapu SS, Nair R, Steiner RE, Iyer SP, Rodriguez A, Fayad LE, Flowers CR, Dabaja BS, Pinnix CC. The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma 62(6):1361-1369, 2021. e-Pub 2021. PMID: 33480830.
38. Tevaarwerk A, Denlinger CS, Sanft T, Ansbaugh SM, Armenian S, Baker KS, Broderick G, Day A, Demark-Wahnefried W, Dickinson K, Friedman DL, Ganz P, Goldman M, Henry NL, Hill-Kayser C, Hudson M, Khakpour N, Koura D, McDonough AL, Melisko M, Mooney K, Moore HCF, Moryl N, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Patel C, Peterson L, Pirl W, Rodriguez MA, Ruddy KJ, Schapira L, Shockney L, Smith S, Syrjala KL, Zee P, McMillian NR, Freedman-Cass DA. Survivorship, Version 1.2021. J Natl Compr Canc Netw 19(6):676-685, 2021. e-Pub 2021. PMID: 34214969.
39. Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil L, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang ML, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins M, Johnson N, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers C, Westin J, Neelapu SS. Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma. Blood. e-Pub 2021. PMID: 33534891.
40. Strati, P; Jain, P; Johnson, RJ; Forbes, S; Feng, L; Samaniego, F; Rodriguez, MA; Fayad, LE; Hagemeister, F; Westin, J; Wang, M; Neelapu, SS; Nastoupil, LJ; Fowler, NH. Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma. Blood Articles 137(8):1124-1129, 2021.
41. Samaniego F, McLaughlin P, Neelapu SS, Feng L, Fanale M, Nastoupil L, Rodriguez MA, Pro B, Taylor E, Hagemeister FB, Fowler N. Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. Leuk Lymphoma 62(1):58-67, 2021. e-Pub 2020. PMID: 32924687.
42. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Yehia Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 41(5):1546, 2019. e-Pub 2019. PMID: 30990235.
43. Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma:1-8. e-Pub 2017. PMID: 28792260.
44. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 39(6):1095-1100, 2017. e-Pub 2017. PMID: 28370694.
45. Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad L, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler N, Turturro F, Westin J, Wang M, McLaughlin P, Pinnix C, Milgrom S, Dabaja B, Horowitz SB, Younes A. Encouraging activity for R-CHOP in Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma. Blood 130(4). e-Pub 2017. PMID: 28522441.
46. Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. Oncologist 22(5):549-553, 2017. e-Pub 2017. PMID: 28408615.
47. Ho JC, Dabaja BS, Milgrom SA, Smith GL, Reddy JP, Mazloom A, Young KH, Deng L, Medeiros LJ, Dong W, Allen PK, Andraos TY, Fowler NH, Nastoupil LJ, Oki Y, Fayad LE, Turturro F, Neelapu SS, Westin J, Hagemeister FB, Rodriguez MA, Pinnix CC. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma(). Leuk Lymphoma:1-12. e-Pub 2017. PMID: 28482717.
48. Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. Br J Haematol 177(2):263-270, 2017. e-Pub 2017. PMID: 28340281.
49. Cheng L, DeJesus AY, Rodriguez MA. Using Laboratory Test Results at Hospital Admission to Predict Short-term Survival in Critically Ill Patients With Metastatic or Advanced Cancer. J Pain Symptom Manage. e-Pub 2017. PMID: 28062337.
50. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer 122(20):3145-3151, 2016. e-Pub 2016. PMID: 27351173.
51. Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol 175(2):290-299, 2016. e-Pub 2016. PMID: 27448187.
52. Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol. e-Pub 2016. PMID: 27378601.
53. Denlinger CS, Ligibel JA, Are M, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Jones LW, King A, Ku GH, Kvale E, Langbaum TS, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Rodriguez MA, Ruddy KJ, Sanft T, Silverman P, Smith S, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA. NCCN Guidelines Insights: Survivorship, Version 1.2016. J Natl Compr Canc Netw 14(6):715-24, 2016. PMID: 27283164.
54. Crosby MA, Cheng L, DeJesus AY, Travis EL, Rodriguez MA. Provider and Patient Gender Influence on Timing of Do-Not-Resuscitate Orders in Hospitalized Patients with Cancer. J Palliat Med. e-Pub 2016. PMID: 27159269.
55. Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol. e-Pub 2016. PMID: 27227654.
56. Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol. e-Pub 2016. PMID: 27091808.
57. Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang ML, Romaguera JE. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol 172(1):80-8, 2016. e-Pub 2015. PMID: 26648336.
58. Akhtari M, Reddy JP, Pinnix CC, Allen PK, Osborne EM, Gunther JR, Milgrom SA, Smith GL, Wogan CF, Fowler N, Rodriguez MA, Dabaja B. Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy. Leuk Lymphoma 57(1):34-8, 2016. e-Pub 2015. PMID: 25860237.
59. Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol. e-Pub 2016. PMID: 26802151.
60. Wu X, Hildebrandt MA, Ye Y, Chow WH, Gu J, Cunningham S, Zhao H, Hawk ET, Wagar E, Rodriguez A, Hamilton SR. Cohort Profile: The MD Anderson Cancer Patients and Survivors Cohort (MDA-CPSC). Int J Epidemiol. e-Pub 2015. PMID: 26686840.
61. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk. e-Pub 2015. PMID: 26795083.
62. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 171(4):509-16, 2015. e-Pub 2015. PMID: 26260306.
63. Palos GR, Lewis-Patterson P, Gilmore K, DeJesus Y, Rodriguez AM. Changing Nursing Practice in Survivorship Care With Clinical Decision Tools. Clin J Oncol Nurs 19(4):482-4, 488, 2015. PMID: 26207716.
64. Oki Y, Neelapu SS, Fanale M, Kwak LW, Fayad L, Rodriguez MA, Wallace M, Klinger M, Carlton V, Kong K, Faham M, Younes A. Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach. Br J Haematol 169(5):689-93, 2015. e-Pub 2015. PMID: 25818067.
65. Youssef B, Shank J, Reddy JP, Pinnix CC, Farha G, Akhtari M, Allen PK, Fanale MA, Garcia JA, Horace PH, Milgrom S, Smith GL, Nieto Y, Arzu I, Wang H, Fowler N, Rodriguez MA, Dabaja B. Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphoma. Radiat Oncol 10:206, 2015. e-Pub 2015. PMID: 26407853.
66. Gallagher CM, Farroni JS, Moore JA, Nates JL, Rodriguez MA. The Misleading Vividness of a Physician Requesting Futile Treatment. Am J Bioeth 15(8):52-3, 2015. PMID: 26225522.
67. Mathur R, Sehgal L, Braun FK, Berkova Z, Romaguerra J, Wang M, Rodriguez MA, Fayad L, Neelapu SS, Samaniego F. Targeting Wnt pathway in mantle cell lymphoma-initiating cells. J Hematol Oncol 8:63, 2015. e-Pub 2015. PMID: 26048374.
68. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. e-Pub 2014. PMID: 25039868.
69. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165(1):112-6, 2014. e-Pub 2014. PMID: 24386943.
70. Herrera AF, Crosby-Thompson A, Friedberg JW, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Millenson MM, Nademanee AP, Niland JC, Rodig SJ, Rodriguez MA, Zelenetz AD, Lacasce AS. Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. Cancer. e-Pub 2014. PMID: 24706502.
71. Rodriguez MA, DeJesus AY, Cheng L. Use of Chemotherapy Within the Last 14 Days of Life in Patients Treated at a Comprehensive Cancer Center. JAMA Intern Med, 2014. e-Pub 2014.
72. Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Kelly J, Millenson M, Nademanee AP, Rodriguez MA, Zelenetz AD, Niland J, LaCasce AS, Friedberg JW. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Br J Haematol 163(4):487-95, 2013. e-Pub 2013. PMID: 24111533.
73. Abou-Nassar KE, Vanderplas A, Friedberg JW, Abel GA, Niland J, Rodriguez MA, Czuczman MS, Millenson M, Crosby A, Gordon LI, Zelenetz AD, Kaminski M, Lacasce AS. Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database. Leuk Lymphoma 54(10):2155-62, 2013. e-Pub 2013. PMID: 23343180.
74. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective Phase II Study of Rituximab with Alternating Cycles of Hyper-CVAD and High-Dose Methotrexate with Cytarabine for Young Patients with High-Risk Diffuse Large B-Cell Lymphoma. Br J Haematol. e-Pub 2013. PMID: 24117234.
75. Evens AM, Vanderplas A, Lacasce AS, Crosby AL, Nademanee AP, Kaminski MS, Abel GA, Millenson M, Czuczman MS, Rodriguez MA, Niland J, Zelenetz AD, Gordon LI, Friedberg JW. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: A comprehensive analysis from the NCCN lymphoma outcomes project. Cancer 119(20):3662-3671, 2013. e-Pub 2013. PMID: 23921646.
76. Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, Podoloff D, Oki Y, Hagemeister FB, Chuang H, Fayad LE, Westin JR, Shihadeh F, Allen PK, Wogan CF, Rodriguez MA. Clinical Implications of PET-Negative Residual CT Masses after Chemotherapy for Diffuse Large B-Cell Lymphoma. Leuk Lymphoma. e-Pub 2013. PMID: 23488661.
77. Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB. The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP. Clin Lymphoma Myeloma Leuk 13(1):15-8, 2013. e-Pub 2012. PMID: 23137719.
78. Abel GA, Vanderplas A, Rodriguez MA, Crosby AL, Czuczman MS, Niland JC, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, LaCasce AS. High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma 53(6):1113-6, 2012. e-Pub 2012. PMID: 22098406.
79. Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer 118(11):2944-51, 2012. e-Pub 2011. PMID: 22006274.
80. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A Randomized Trial of a Single-Dose Rasburicase Versus Five-Daily Doses in Patients at Risk for Tumor Lysis Syndrome. Annals of Oncology 23(6):1640-5, 2012. e-Pub 2011.
81. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase II study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 119(18):4123-8, 2012. e-Pub 2012. PMID: 22371887.
82. Batty N, Hagemeister FB, Feng L, Romaguera JE, Rodriguez MA, McLaughlin P, Samaniego F, Copeland A, Dabaja BS, Younes A. Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study. Leuk Lymphoma 53(5):801-6, 2012. e-Pub 2012. PMID: 22023528.
83. Lacasce AS, Vandergrift JL, Rodriguez MA, Abel GA, Crosby AL, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Lepisto EM, Zelenetz AD, Niland J, Friedberg JW. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood 119(9):2093-9, 2012. e-Pub 2012. PMID: 22234679.
84. Phan J, Mazloom A., Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, Horace P, Dabaja BS. Benefit of Consolidative Radiation Therapy in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Chemotherapy. Journal of Clinical Oncology. e-Pub 2010.
85. Rodriguez MA, Tortorella F, St John C. Improving Psychosocial Care for Improved Health Outcomes. J Healthc Qual 32(32/4):3-13, 2010. PMID: 20618566.
86. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez A, Samaniego F, McLaughlin PW, Hagemeister FB, Neelapu SS, Copeland AR, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II Study of Yttrium-90 (90Y)-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory Mantle Cell Lymphoma. Journal of Clinical Oncology 27(31):5213-8, 2009.
87. Rodriguez MA, Pytlik R, Kozak T, Chhanabhai M, Gascoyne R, Lu B, Deitcher SR, Winter JN. Vincristine Sulfate Liposomes Injection (Marqibo) in Heavily Pretreated Patients with Refractory Aggressive non-Hodgkin Lymphoma: Report of the Pivotal Phase 2 Study. Cancer 115(15):3475-3482, 2009. PMID: 19536896.
88. Rodriguez MA, Storm CD, Burris, III HA. Medical Errors: Physician and Institutional Responsibilities. Journal of Oncology Practice 5(1), 2009.
89. Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, Kwak LW, Zhou Y, Kantarjian H, Romaguera J. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer 113(10):2734-41, 2008. PMID: 18973182.
90. Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Rodriguez A, McLaughlin P, Samaniego F, Zwiebel J, Lopez A, Kwak L, Younes A. Phase II Multicenter Study of Oblimersen Sodium, a Bcl-2 Antisense Oligonucleotide, in Combination with Rituximab in Patients with Recurrent B-cell Non-Hodgkin Lymphoma. British Journal of Haematology, 2008. e-Pub 2008.
91. Russell NC, Hoelscher DM, Janszen L, Rodriguez MA. Dietary and weight changes after treatments for lymphoma. Nutr Cancer 57(2):168-76, 2007. PMID: 17571950.
92. Liu Q, Fayad L, Cabanillas F, Hagemeister F, Ayers G, hess M, Romaguera R, Rodriguez A, Tsimberidou A, Verstovsek S, Younes A, Pro B, Lee M, Ayala A, McLaughlin P. Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 years of Treatment Experience at The University of Texas M. D. Anderson Cancer Center. J. Clin. Oncol 24, No. 10:1582-1589, 2006.
93. Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 22:4095-102, 2004. PMID: 15353540.
94. Cohen L, Warneke C, Fouladi RT, Rodriguez MA. Psychological adjustment and sleep quality in a randomized trial of the effects of a Tibetan yoga intervention in patients with lymphoma. Cancer 100(10):2253-2260, 2004.
95. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, Goy A, Jeha S, Manning JT, Jr, Jones D, Abruzzo LV, Medeiros LJ. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 98:310-4, 2003. PMID: 12872350.
96. Lee HK, Wilder RB, Jones D, Ha CS, Pro B, Rodriguez MA, Romaguera JE, Cabanillas F, Rodriguez J, Cox JD. Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. Leuk Lymphoma 43:1769-75, 2002. PMID: 12685830.
97. Wilder RB, Rodriguez MA, Medeiros LJ, Tucker SL, Ha CS, Romaguera JE, Pro B, Hess MA, Cabanillas F, Cox JD. International prognostic index-based outcomes for diffuse large B-cell lymphomas. Cancer 94:3083-8, 2002. PMID: 12115338.
98. Wilder RB, Rodriguez MA, Ha CS, Pro B, Hess MA, Cabanillas F, Cox JD. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Cancer 91(12):2440-6, 2001. PMID: 11413536.
99. Rodriguez J, McLaughlin P, Fayad L, Santiago M, Hess M, Rodriguez MA, Romaguera J, Hagemeister F, Kantarjian H, Cabanillas F. Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981. Ann Oncol 11(12):1551-6, 2000. PMID: 11205462.
100. Rodriguez J, McLaughlin P, Hagemeister FB, Fayad L, Rodriguez MA, Santiago M, Hess M, Romaguera J, Cabanillas F. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood 93(7):2202-7, 1999. PMID: 10090928.
101. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, Forman A, Romaguera J, Hagemeister F, Younes A, Bachier C, Sarris A, Sobocinski KS, Cox JD, Cabanillas F. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91(4):1178-84, 1998. PMID: 9454747.
102. Rodriguez MA. Factors that influence prognosis of intermediate-grade lymphomas at relapse. Cancer Treat Res 85:79-86, 1996. PMID: 9043776.
103. McLaughlin P, Hagemeister FB, Swan F, Jr, Cabanillas F, Pate O, Romaguera JE, Rodriguez MA, Redman JR, Keating M. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 12:575-9, 1994. PMID: 8120556.
104. Woo SY, Fuller LM, Cundiff JH, Bondy ML, Hagemeister FB, McLaughlin P, Velasquez WS, Swan F, Jr, Rodriguez MA, Cabanillas F, et al. Radiotherapy during pregnancy for clinical stages IA-IIA Hodgkin's disease. Int J Radiat Oncol Biol Phys 23:407-12, 1992. PMID: 1587764.

Manuals, Teaching Aids, Other Teaching Publications

1. Polansky M, Rodriguez MA. Introduction to Clinical Oncology e-Course, 2009.

Abstracts

1. Chihara, Dai ; Nastoupil, Loretta ; Strati, Paolo ; Samaniego, Felipe ; Feng, Lei ; Rodriguez, Maria Alma ; Fayad, Luis ; Westin, Jason R ; Hagemeister, Fredrick B ; Wang, Michael ; Neelapu, Sattva S ; Fowler, Nathan H. Ten Year Follow up of the MD Anderson Cancer Center Phase 2 Study of Rituximab in Combination with Lenalidomide (R2) for Patients with Low Tumor Burden Follicular Lymphoma. Blood 138:3532, 2021.
2. Westin, Jason R ; Steiner, Raphael ; Feng, Lei ; Strati, Paolo ; Flowers, Christopher R ; Neelapu, Sattva S ; Nastoupil, Loretta ; Chihara, Dai ; Hagemeister, Fredrick B ; Ahmed, Sairah ; Nair, Ranjit ; Fayad, Luis ; Lee, Hun Ju ; Rodriguez, Maria Alma ; Davis, Eric ; Green, Michael R. Smart Stop: A Phase II Study of Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Chemotherapy in Patients with Newly Diagnosed DLBCL. Blood 138:3572, 2021.
3. Steiner, Raphael E ; Strati, Paolo ; Flowers, Christopher R ; Neelapu, Sattva S ; Green, Michael R ; Nastoupil, Loretta ; Hagemeister, Fredrick B ; Feng, Lei ; Ahmed, Sairah ; Nair, Ranjit ; Fayad, Luis ; Lee, Hun Ju ; Rodriguez, Maria Alma ; Westin, Jason R. Pacific: A Phase II Study of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma. Blood 138:1408, 2021.
4. Cherng, Hua-Jay J ; Sun, Ryan ; Yang, Haopeng ; Deng, Qing ; Fayad, Luis ; Fowler, Nathan H ; Parmar, Simrit ; Ahmed, Sairah ; Steiner, Raphael E ; Hagemeister, Fredrick B ; Lee, Hun Ju ; Nair, Ranjit ; Rodriguez, Maria Alma ; Samaniego, Felipe ; Iyer, Swaminathan P ; Nastoupil, Loretta ; Neelapu, Sattva S ; Strati, Paolo ; Westin, Jason R ; Green, Michael R. A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma. Blood 138:38, 2021.
5. Nair, Ranjit ; Deen, Nafis ; Ahmed, Sairah ; Miranda, Roberto N ; Fowler, Nathan H ; Fayad, Luis ; Steiner, Raphael E ; Hagemeister, Fredrick B ; Rodriguez, Maria Alma ; Lee, Hun Ju ; Strati, Paolo ; Malpica-Castillo, Luis ; Chihara, Dai ; Jain, Preetesh ; Gunther, Jillian R ; Flowers, Christopher R ; Medeiros, L. Jeffrey ; Nieto, Yago ; Ramdial, Jeremy L ; Neelapu, Sattva S ; Nastoupil, Loretta ; Green, Michael R ; Wang, Michael ; Vega, Francisco ; Feng, Lei ; Iyer, Swaminathan Padmanabhan ; Westin, Jason R. Outcome of Patients with T- Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series. Blood 138:1448, 2021.
6. Pinnix, Chelsea C ; Dabaja, Bouthaina S ; Gunther, Jillian R ; Fang, Penny ; Wu, Susan ; Nastoupil, Loretta ; Strati, Paolo ; Nair, Ranjit ; Ahmed, Sairah ; Steiner, Raphael E ; Malpica-Castillo, Luis ; Chihara, Dai ; Jain, Preetesh ; Fayad, Luis ; Westin, Jason R ; Neelapu, Sattva S ; Rodriguez, Maria Alma ; Hagemeister, Fredrick B ; Lee, Hun Ju ; Wang, Michael ; Samaniego, Felipe ; Fowler, Nathan H ; Flowers, Christopher R ; Feng, Lei ; Chi, Linda ; Esmaeli, Bita. Phase II Trial of Response Adapted Ultra Low Dose (ULD) Orbital Radiation Therapy for Indolent B Cell Lymphoma. Blood 138:3526, 2021.
7. Gilmore, Katherine Ramsey, Chapman, Patricia Hansberry, Palos, Guadalupe R, Rodriguez, Maria Alma. Patterns of virtual care among long-term cancer survivors. Journal of Clinical Oncology 39:335-335, 2021.
8. Pai A, Ferrajoli A, Cheng L, Huynh T, Rodriguez MA. Comparison of Normal Saline Versus Heparin Flush Solutions for Maintaining Patency of Central Venous Catheter in Cancer Patients. Journal of Clinical Oncology 37(suppl), 2019.
9. Strati P, Ahmed MA, Fowler NH, Hagemeister FB, Fayad L, Rodriguez MA, Samaniego F, Wang M, Westin J, Romaguera JE, Noorani M, Phansalkar K, Cheah C, Feng L, Davis RE, Nastoupil LJ, Neelapu SS. Prognostic Value of Baseline SUVmax in Patients with Advanced Stage Follicular Lymphoma Receiving Frontline Rituximab-based Therapy. Journal of Clinical Oncology 37(suppl), 2019.
10. Westin J, Nastoupil LJ, Fayad L, Hagemeister FB, Oki Y, Turturro F, Ahmed S, Rodriguez MA, Lee HJ, Steiner R, Nair R, Parmar S, Young KH, McDonnell T, Chuang H, Green MR, Neelapu SS, Davis RE. Smart start: Final Results of Rituximab, Lenalidomide, and Ibrutinib Lead in Prior to Combination with Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma. Journal of Clinical Oncology 37(suppl), 2019.
11. Rodriguez MA, Palos GR, Gilmore KR, Lewis-Patterson PA, Chapman P, Bi W. Analysis of Financial Sustainability of Survivorship Clinics Led by Advanced Practice Providers. Journal of Clinical Oncology 37(suppl), 2019.
12. Bell, M, Stepan, K, Meyer, M, Anderson, J, Calhoun, J, Guzman, A, Thomas, J, Rodriguez, MA, and Valentine, A. Building the Case for a Value-Based Integrated Mental Health Services Access and Financial Model for a Comprehensive Cancer Center. International Psycho-Oncology Congress Conference, 2016.
13. Bell, M, Stepan, K, Meyer, M, Anderson, J, Calhoun, J, Guzman, A, Thomas, J, Rodriguez, MA, and Valentine, A. Defining the Value of Psychosocial Services for Cancer Care Patients. International Psycho-Oncology Congress Conference, 2016.
14. Palos GR, Zandstra F, Bevers T, Gilmore K, Greer M, Rodriguez MA. Improving Survivors' Quality of Care Through Use of Self-Reported Satisfaction Data. AACR Journal Cancer Research, 2015. e-Pub 2015.
15. Rodriguez MA, DeJesus AY, Cheng L, Kroll M. Practice of venous thromboembolism (VTE) prophylaxis in hospitalized cancer patients at a comprehensive cancer center. J Clin Oncol 32(5s):440s, 2014.
16. Rodriguez MA, Sanchez-Espiridion B, Gu J, Wu X, Zandstra F, Palos G. Leukocyte telomere length and risk of secondary primary tumors in long-term breast cancer suvivors. J Clin Oncol 32(5s):626s, 2014.
17. Palos G, Zandstra F, Simar K, Russell L, Ozeri D, Bi W, Rodriguez MA. Tobacco use among lymphoma survivors. J Clin Oncol 32(suppl), 2014.
18. Nastoupil L, Neelapu S, Samaniego F, Hagemeister F, Romaguera J, Kwak L, Wang M, Fayad L, Fanale M, Oki Y, Westin J, Rodriguez MA, Cabanillas F, McLaughlin P, Fowler N. 10-year remission rates following rituximab (R) and FND chemotherapy (fludarabne, mitozantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: Results of a randomized study. J Clin Oncol 32(5s):545s, 2014.
19. Fingeret M, Palos GR, Stepan K, Tortorella F, Rodriguez MA. Establishment and Growth of a Psychosocial Council to Address Institutional Needs Within a Comprehensive Cancer Center. Psycho-Oncology 23(Supp S1):22-23, 2014.
20. Dabaja B, Vanderplas A, Abel G, Czuczman MS, Friedberg J, Gordon LI, Kaminski M, LaCasce AS, Millenson M, Niland J, Nademanee AP, Zelenetz A, Crosby-Thompson AL, Rodriguez MA. Role of Radiation in Patients with Diffuse Large B-cell Lymphoma (DLBCL) in the Rituximab Era: A Comprehensive Analysis from the National Comprehensive Cancer Network (NCCN) Lymphoma Outcomes Project. Hematolo Oncol 31(S1):136, 2013.
21. Zhou Z, Rademaker A, Gordon LI, LaCasce AS, Crosby-Thompson A, Vanderplas A, Rodriguez MA, Zelenetz AD, Abel A, Nademanee A, Kaminski MS, Cuzczman M, Milleson MM, Niland JC, Friedberg JW, Winter JN. Impact of Gender, Body Mass Index and Body Surface Area on Outcomes of Diffuse Large B-cell Lymphoma Patients Treated with Rituximab: Analysis of the U.S. National Comprehensive Cancer Network Database. Hematol Oncol 31(S1):166, 2013.
22. Burke T, DeJesus Y, Cheng L, Buzdar A, Rodriguez MA. Pattern of Chemotherapyuse at the End-of-life in Patients with Solid Tumors (ST). 2013 ASCO Annual Meeting Proceedings 31(15 (Suppl)), 2013.
23. Rodriguez MA, DeJesus YA, Cheng L, Buzdar A, Burke T. Factors Related to End-of-life Chemotherapy in Solid Tumor (ST) Patients. 2013 ASCO Annual Meeting Proceedings 31(15(Suppl)), 2013.
24. Vadhan-Raj S, Fayad L, Fanale M, Pro B, Rodriguez A, Hagemeister F, Ames K, Bueso-Ramos C, Zhou X, McLaughlin P, Fowler N, Shah J, Samaniego F, Younes A, Kwak L, Romaguera J. Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing vs. a Single Dose Followed By As Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome. Blood 114(22), 2009.
25. LaCasce A, Vandergrift JL, Rodriguez MA, Crosby AL, Lepisto EM, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Abel GA, Zelenetz AD, Friedberg JW. R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: A Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin’s Lymphoma Outcomes Database Project. Blood 114(22), 2009.
26. Jones D, Windham J, Stewart B, Fayad L, Rodriguez A, Hagemeister FB. Differential JAK-STAT Pathway Activation in Primary Mediastinal Large B-Cell Lymphoma: Two Subgroups with Differential Cytokine Activation Patterns and Predicted Responses to Kinase Inhibitors. Blood 114(22), 2009.
27. Abel GA, Vanderplas A, Friedberg JW, Niland J, Rodriguez MA, Czuczman MS, Millenson M, Crosby AL, Gordon LI, BlayneyDW, Zelenetz AD, LaCasce AS. Variations in Surveillance Imaging for Patients with Treated Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database. Blood 114(22), 2009.
28. Copeland AR, Cao Y, Fanale M, Fayad L, McLaughlin P, Pro B, Hagemeister F, Romaguera J, Samaniego F, Rodriguez A, Younes A. Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Results of Long Follow Up and Comparison to Institutional Historical Data. Blood 114(22), 2009.
29. Westin JR, Thompson MA, Cataldo VD, Toth BB, Sanjorjo P, Bourgeois S, Jimenez C, Murphy WA, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F. Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response. Blood 114(22), 2009.
30. Habra MA, Thompson MA, Rodriguez MA, Routbort MJ, Holsinger FC, Perrier ND, Waguespack SG: Primary Natural Killer/T Cell Lymphoma of the Adrenal Gland: A Unique Presentation of a Rare Disorder. Primary Natural Killer/T Cell Lymphoma of the Adrenal Gland: A Unique Presentation of a Rare Disorder. The Endocrine Society's 87th Annual Meeting 87th Annual Meeting, 2005.
31. Ferrajoli A, DeJesus Y, Cheng L, Rodriguez MA. Incidence rate of venous thromboembolism (VTE) and utilization of a VTE prophylaxis orderset module in hospitalization patients with leukemia.
32. Rodriguez MA. Clinical algorithms to manage symptoms and late effects of cancer in long-term survivors. 2014 Palliative Care Oncology Symposium.
33. Zandstra F, Palos GR, Russill L, Bi W, Ozeri D, Gilmore K, Rodriguez MA. Auditing Clinicians' Concordance with Practice Algorithms Tailored for Adult Survivors of Diffuse Large B-Cell Lymphoma and Hodgkin's Lymphoma. Cancer.
34. Palos GR, Zandstra F, Russell L, Gilmore K, Flores J, Ozeri D, Leong C, Nguyen D, Patel M, Rodriguez MA. Planning Cancer Wellness Survivorship Programs for Community-Based Adult Survivors. Cancer.
35. Palos GR, Gilmore KR, Chapman P, Bi W, Lewis-Patterson P, Rodriguez MA. Patterns of Providers' Mammagram Referrals for Asymptomatic Breast Cancer Survivors. National Comprehensive Cancer Network (NCCN) Improving the Quality, Effectiveness, and Efficiency of Cancer Care™.

Book Chapters

1. Rodriguez MA, Lewis-Patterson P, Palos G. Chapter 5: Ethical Issues in Cancer Survivorship. In: Ethical Challenges in Oncology. Academic Press, An Imprint of Elsevier: London, United Kingdom, 85-98, 2017.
2. Ratan R, Ater J, Rieber A, Rodriguez MA. Long-Term Survivorship in Adult and Pediatric Cancer. In: The MD Anderson Manual of Medical Oncology, Third Edition. 3rd. McGraw-Hill Education: China, 1211, 2016.
3. Rodriguez MA. Introduction. In: Advances in Cancer Survivorship. 1st. Springer: New York, 1-4, 2014.
4. Rodriguez MA, Zandstra F. Models of Survivorship Care. In: Advances in Cancer Survivorship. 1st. Springer: New York, 7-25, 2014.
5. Rodriguez MA, Ballas L, and Simar K. Hematologic Cancer Survivorship Management: Lymphoma. In: Advances in Cancer Survviorship. 1st. Springer: New York, 201-218, 2014.
6. Rodriguez MA. Introduction. In: 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. Springer: New York, 1-3, 2012.
7. Rodriguez MA. Non-Hodgkin Aggressive B-Cell Lymphoma. In: 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. Springer: New York, 251-262, 2012.
8. Fayad L, Konoplev S, Chuang H, Rodriguez MA, Commentary: Dabaja BS. Aggressive and Highly Aggressive B-Cell Lymphomas. In: The MD Anderson Manual of Medical Oncology. 2. McGraw-Hill: USA, 147-182, 2011.
9. Holm MJ, Selvan M, Smith ML, Markman M, theriault R, Rodriguez MA, Martin S. Quality Improvement or Research: Defining and Supervising Q1 at the University of Texas M. D. Anderson Cancer Center. In: Health Care Quality Improvement: Ethical and Regulatory Issues. The Hastings Center: Garrison, New York, 2007.
10. Rodriguez MA, Sneed T, Kantarjian HM, Wolff RA, Koller CA. Aggressive and Highly Aggressive Lymphomas. In: M.D. Anderson Manual of Medical Oncology. McGraw-Hill Publishers, 101-140, 2006.
11. Rodriguez MA Bseiso AW. Lymphomas of the Head and Neck: Chapter 34. In: Head and Neck Cancer: A Multidisciplinary Approach. Lippincott-Raven Publishers, 2004.
12. Rodriguez MA Cabanillas F. Prognostic Factors in Non-Hodgkin’s Lymphoma. BC Decker Inc. Publisher, 2001.
13. Pro B Rodriguez A. Gastric Cancer in the MD Anderson Solid Tumor Oncology Series. In: Management of Primary Gastric Lymphoma. Springer-Verlag, 1999.
14. Melnyk A Rodriguez MA. Intermediate and High Grade non-Hodgkin's Lymphomas. In: Chapter 6 Medical Oncology: A Comprehensive Review. PRR, 1996.
15. Rodriguez MA, Cabanillas FC, Deisseroth AB. Non-Hodgkin's lymphoma. In: Hematology: A Problem-Solving Approach. Lea & Febringer, 1996.
16. Rodriguez MA Hong WK. Diagnosis and Management of Lymphomas in the Head and Neck: Chapter 32. In: Cancer of the Head and Neck. W.B. Saunders, 1996.
17. Rodriguez MA Pugh W. Mantle Cell Lymphomas: Chaper 4. In: Advances in Lymphoma Research. Kluwer Academic Publishers, 1996.
18. Rodriguez MA, Romaguera JE, Swan F, Cabanillas FC, McLaughlin P. Prognostic variables in low-grade lymphomas. In: Autologous Bone Marrow Transplantation for Hodgkin's Disease, Non-Hodgkin's Lymphoma and Multiple Myeloma. Springer-Verlag, 1993.
19. Rodriguez MA Hong WK. Lymphomas presenting in the head and neck: Current issues in diagnosis and management. In: Advances in Otolaryngology -Head and Neck Surgery. Mosby Yearbook, 1991.
20. Rodriguez MA Cabanillas F. Linfomas de linfocitos T perifericos y otras entidades relacionadas. In: Chapter 6, in Linfomas. Editorial Doyma, 1988.
21. Rodriguez MA Cabanillas F. Evaluacion y manejo de los linfomas de alto grado. In: Chapter 7, in Linfomas. Editorial Doyma, 1988.
22. Rodriguez MA Meyskens FL. Chemosensitivity testing techniques applied to human melanoma. In: Contemporary Issues In Clinical Oncology - Management Of Advanced Melanoma. Churchill Livingstone, 91-99, 1986.

Books (edited and written)

1. Foxhall L, Rodriguez MA. Advances in Cancer Survivorship Management. Ed(s) Foxhall L and Rodriguez MA. 1ed. Springer: New York, 2014.
2. Rodriguez MA, Walters RS, Burke TW, Eds.. 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. Springer: New York, 346, 2012.
3. Cabanillas FC Rodriguez MA. Advances in Lymphoma Research. Kluwer Academic Publishers, 1996.